Who we are

Our sole focus is to develop technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to healthy tissues. Our goal is to help healthcare providers and hospitals expand their repertoire of treatments to ensure clinicians and patients have choices. Advanced Oncotherapy's aim is to cost-effectively deliver the next generation of proton therapy which is clinically superior to the currently available alternative radiation therapies.

Advanced Oncotherapy plc has its head office in London, UK, an R&D/ADAM facility located on the campus of CERN, Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, USA.

Advanced Oncotherapy plc is a public limited company in England and Wales; company number 05564418 with registered offices on Level 17, Dashwood House, 69 Old Broad Street, London, EC2M 1QS. The Company’s shares are listed on the AIM market of the London Stock Exchange under the symbol AVO.L

Values

We have a strong foundation of core company values which underpin everything we do.

Read more

Strategy

Our strategy is to provide wider and cost-effective access to radiation treatment through a ground-breaking proton therapy system with superior clinical benefits for cancer patients.

Read more

Leadership Team

Our team is made up of highly skilled professionals who have a wide range of experience in their field.

Read more

History

Advanced Oncotherapy was created in 2012, leveraging the work and know-how of CERN experts in accelerator and detector technologies.

Read more

Directors

Our board brings entrepreneurial, commercial and financial leadership.

Read more

Advisers

Their expertise and experience are unmatched. Combined they have over 100 years in radiation oncology and over 45 years of treating patients with proton therapy from around the world.

Read more

Corporate governance

Advanced Oncotherapy is committed to the highest standards of corporate governance, business integrity and professionalism. The Directors recognise the importance of sound corporate governance.

Read more